Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 19;12:1048127. doi: 10.3389/fonc.2022.1048127

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Guo, Lu and Xiong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Construction of eRNA-based prediction models for irAE ROR (risk) and ORR (benefit) of immunotherapy. (A) The step-by-step workflow of this study. (B) Multicollinearity (VIF) analysis for top ten eRNA expression in predicting irAEs. Six eRNAs showed no multicollinearity, while 4 eRNAs showed strong multicollinearity. (C) Spearman correlation (Rs) between irAE-correlated eRNAs. The shade of the square indicates the Rs, and the size indicates significance (* indicates statistical significance P < 0.05). (D) Combined effects of the final trivariate model of predicting irAEs (R=0.84, P=2.1e-6). The model is 0.1912*ENSR00000005553+0.4097*ENSR00000326714+0.1953*ENSR00000148786+0.2942. (E) Multicollinearity analysis for top ten eRNA expression in predicting ORR. Two eRNAs showed no multicollinearity, while 8 eRNAs showed strong multicollinearity. (F) Spearman correlation between ORR-correlated eRNAs. The shade of the square indicates the Rs, and the size indicates P-value (* indicates statistical significance P< 0.05). (G) Combined effects of the final model of predicting ORR (R=0.89, P=3.3e-7). The model is 0.0953 + 0.0649*ENSR00000164478+0.0032*ENSR00000035913+0.1687*ENSR00000167231. irAE, immune-related adverse events; ROR, reporting odds ratio; ORR, objective response rates; LUAD, lung adenocarcinoma; SKCM, skin cutaneous melanoma; LUSC, lung squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; PRAD, prostate adenocarcinoma; BLCA, bladder urothelial carcinoma; MESO, mesothelioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; SARC, sarcoma; ESCA, esophageal carcinoma; PAAD, pancreatic adenocarcinoma; OV, ovarian serous cystadenocarcinoma; HNSC, head and neck squamous cell carcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; CHOL, cholangiocarcinoma; ACC, adrenocortical carcinoma; READ, rectum adenocarcinoma; COAD, colon adenocarcinoma; LIHC, liver hepatocellular carcinoma; LGG, brain lower-grade glioma; GBM, glioblastoma multiforme; UVM, uveal melanoma; UCS, uterine carcinosarcoma.